<DOC>
	<DOCNO>NCT00030888</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness UCN-01 treating patient unresectable stage III stage IV kidney cancer .</brief_summary>
	<brief_title>UCN-01 Treating Patients With Advanced Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy UCN-01 , term time objective progression , patient stage IV unresectable stage III renal cell carcinoma . - Determine objective response rate patient treat drug . OUTLINE : Patients receive UCN-01 IV 3 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 21-61 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV unresectable stage III renal cell carcinoma Metastatic disease must amenable biopsy appropriate nephrectomy study therapy At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan No known prior concurrent CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST/ALT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No history clinically significant coronary artery disease No symptomatic cardiac dysfunction No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Pulmonary : No symptomatic pulmonary dysfunction Other : No prior allergic reaction compound similar chemical biological composition UCN01 No uncontrolled concurrent illness No active ongoing infection No know immune deficiency No psychiatric illness social situation would preclude study compliance No insulindependent diabetes mellitus Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No prior mediastinal radiation Surgery : See Disease Characteristics At least 4 week since prior nephrectomy Other : No 2 prior systemic therapy metastatic renal cell carcinoma No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>